GSK Adds 330,000 Shares to Treasury in Ongoing Buyback

The latest update is out from GlaxoSmithKline ( (GB:GSK) ).

GSK has continued its ongoing share buyback programme, repurchasing 330,000 ordinary shares on 16 April 2026 through BNP Paribas at a volume-weighted average price of 2,125.06 pence. The shares will be held in treasury, lifting its treasury stock to 259,417,615 shares and leaving 4,056,773,154 shares in issue, with treasury shares now representing 6.39% of voting rights.

Since the launch of its current buyback in February, GSK has acquired 19,526,521 shares, underlining a sustained capital return and balance-sheet management strategy. The updated voting rights figure provides investors with a new reference point for regulatory disclosure thresholds and may support earnings-per-share metrics by reducing the free float over time.

The most recent analyst rating on (GB:GSK) stock is a Hold with a £22.50 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

Spark’s Take on GSK Stock

According to Spark, TipRanks’ AI Analyst, GSK is a Neutral.

The score is driven primarily by strong profitability and improving recent fundamentals, supported by constructive 2026 guidance and pipeline momentum. Valuation is reasonable with a modest yield, while the main constraint is technical overbought risk and ongoing balance-sheet/earnings-consistency considerations.

To see Spark’s full report on GSK stock, click here.

More about GlaxoSmithKline

GSK plc is a global biopharmaceutical company focused on developing and commercialising vaccines and specialty medicines. The group targets major disease areas worldwide and is a large constituent of the UK blue-chip market, with its ordinary shares traded on the London Stock Exchange.

Average Trading Volume: 9,512,590

Technical Sentiment Signal: Buy

Current Market Cap: £85.13B

Find detailed analytics on GSK stock on TipRanks’ Stock Analysis page.